KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,189,881 | +7.4% | 100,059 | +35.4% | 0.00% | 0.0% |
| Q2 2023 | $2,969,583 | +11.7% | 73,907 | +18.7% | 0.00% | 0.0% |
| Q1 2023 | $2,658,502 | -62.0% | 62,260 | -57.3% | 0.00% | -50.0% |
| Q4 2022 | $7,002,373 | +5.5% | 145,822 | -17.3% | 0.00% | 0.0% |
| Q3 2022 | $6,635,000 | +62.4% | 176,364 | +19.3% | 0.00% | +100.0% |
| Q2 2022 | $4,086,000 | -41.2% | 147,851 | +15.7% | 0.00% | 0.0% |
| Q1 2022 | $6,952,000 | -0.4% | 127,831 | +7.2% | 0.00% | 0.0% |
| Q4 2021 | $6,980,000 | +239.8% | 119,298 | +129.8% | 0.00% | – |
| Q3 2021 | $2,054,000 | +115.3% | 51,909 | +131.0% | 0.00% | – |
| Q2 2021 | $954,000 | +143.4% | 22,470 | +253.2% | 0.00% | – |
| Q1 2021 | $392,000 | -95.5% | 6,362 | -94.9% | 0.00% | -100.0% |
| Q4 2020 | $8,741,000 | +1179.8% | 123,915 | +599.4% | 0.00% | – |
| Q3 2020 | $683,000 | – | 17,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |